within Pharmacolibrary.Drugs.ATC.A;

model A16AX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 46 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,
    adminCount     = 1,
    Vd             = 0.00043,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Thioctic acid, also known as alpha-lipoic acid, is a naturally occurring compound with antioxidant properties. It is used mainly as a dietary supplement and has been investigated for use in diabetic neuropathy and as an adjunct in various metabolic or neurological disorders. It is not universally approved as a drug but is used as an over-the-counter supplement in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after oral administration of 600 mg thioctic acid.</p><h4>References</h4><ol><li><p>Brufani, M, &amp; Figliola, R (2014). (R)-α-lipoic acid oral liquid formulation: pharmacokinetic parameters and therapeutic efficacy. <i>Acta bio-medica : Atenei Parmensis</i> 85(2) 108–115. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25245645/&quot;>https://pubmed.ncbi.nlm.nih.gov/25245645</a></p></li><li><p>Hermann, R, et al., &amp; Ziegler, D (2014). Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms. <i>Clinical pharmacology : advances and applications</i> 6 195–204. DOI:<a href=&quot;https://doi.org/10.2147/CPAA.S71574&quot;>10.2147/CPAA.S71574</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25506250/&quot;>https://pubmed.ncbi.nlm.nih.gov/25506250</a></p></li><li><p>Breithaupt-Grögler, K, et al., &amp; Belz, GG (1999). Dose-proportionality of oral thioctic acid--coincidence of assessments via pooled plasma and individual data. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 8(1) 57–65. DOI:<a href=&quot;https://doi.org/10.1016/s0928-0987(98)00061-x&quot;>10.1016/s0928-0987(98)00061-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10072479/&quot;>https://pubmed.ncbi.nlm.nih.gov/10072479</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AX01;
